Drug Profile
Research programme: cancer therapeutics - Neoloch
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Neoloch
- Class Peptides
- Mechanism of Action Erythropoietin receptor agonists; Neural cell adhesion molecule agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Cancer in Denmark (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)
- 04 Jul 2016 Preclinical trials in Cancer in Denmark (Parenteral)